United StatesExpresses support for evidence-based access to mifepristone and telemedicine
The resolution signals congressional support for science-based FDA policy on mifepristone, which could influence debates over access to medication abortion.
What it does
Declares that FDA policies on medication abortion should be grounded in transparent scientific review and consider burdens on patient access.
Affirms that Congress authorized the FDA to regulate drugs based on scientific determinations without political interference.
States that FDA review over 25 years and additional studies have shown mifepristone to be safe and effective, including when prescribed via telemedicine and dispensed by mail or at pharmacies.
Expresses that preserving and expanding access to medication abortion is important to address disparities affecting many named groups.
Argument forMifepristone has a long, well-studied safety record; FDA reviews over 25 years and recent studies support its safety and efficacy, including via telemedicine and pharmacy/mail dispensing, so policy should reflect that evidence.
Argument againstAs a nonbinding 'sense' resolution, it does not change FDA rules, REMS, or state laws, so critics may view it as largely symbolic with limited practical effect on access.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Adopted
Looking ahead
No hearings or votes scheduled.
History
- 2026
- May 14Submitted in HouseLatest
- May 14Referred to the House Committee on Energy and Commerce.Introduced
Reproductive RightsHealthcareCivil Rights & Voting